Literature DB >> 27712588

Knockdown of REV7 Inhibits Breast Cancer Cell Migration and Invasion.

Liu Feng1, Wang Wei, Zhang Heng, Han Yantao, Wang Chunbo.   

Abstract

REV7 (also known as MAD2L2) is a multifunctional protein involved in DNA damage tolerance, cell cycle regulation, gene expression, and carcinogenesis. Although its expression is reportedly associated with poor prognosis in several kinds of human cancers, the significance of REV7 expression in breast malignancies is unclear. In this study, REV7 was found to be increased in breast cancer. We found that knockdown of REV7 inhibited the migration, invasion, and epithelial-mesenchymal transition (EMT) of breast cancer cells. Meanwhile, overexpression of REV7 promoted the migration, invasion, and EMT of breast cancer cells. As shown by Western blot, knockdown of REV7 can promote TGF-β1 expression. Western blot analysis indicated that TGF-β1 may play a role as a downstream factor of REV7. Moreover, interference of TGF-β1 can also inhibit the cell's ability for migration, invasion, and EMT, as well as in a cell line whose REV7 is overexpressed. Taken together, these results contributed to a recognition of the oncogene functions of REV7 in breast cancer cells and provided a novel direction to treat breast cancer.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27712588     DOI: 10.3727/096504016X14666990347590

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  6 in total

Review 1.  Circulating Tumor Cells in Breast Cancer Patients: A Balancing Act between Stemness, EMT Features and DNA Damage Responses.

Authors:  Benedikt Heitmeir; Miriam Deniz; Wolfgang Janni; Brigitte Rack; Fabienne Schochter; Lisa Wiesmüller
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

Review 2.  REV7: Jack of many trades.

Authors:  Inge de Krijger; Vera Boersma; Jacqueline J L Jacobs
Journal:  Trends Cell Biol       Date:  2021-05-04       Impact factor: 20.808

3.  MAD2L2 inhibits colorectal cancer growth by promoting NCOA3 ubiquitination and degradation.

Authors:  Yixin Li; Liren Li; Miao Chen; Xinfa Yu; Zhuoyu Gu; Huijuan Qiu; Ge Qin; Qian Long; Xiaoyan Fu; Tianze Liu; Wenbin Li; Wenlin Huang; Dingbo Shi; Tiebang Kang; Meihua Luo; Xiaojun Wu; Wuguo Deng
Journal:  Mol Oncol       Date:  2018-02-13       Impact factor: 6.603

4.  Neurodevelopmental phenotypes in individuals with pathogenic variants in CHAMP1.

Authors:  Madison Garrity; Haluk Kavus; Marta Rojas-Vasquez; Irene Valenzuela; Austin Larson; Sara Reed; Gary Bellus; Cyril Mignot; Arnold Munnich; Bertrand Isidor; Wendy K Chung
Journal:  Cold Spring Harb Mol Case Stud       Date:  2021-08-02

5.  Knockdown of DNA polymerase ζ relieved the chemoresistance of glioma via inhibiting the PI3K/AKT signaling pathway.

Authors:  Junbao Yang; Weilong Ding; Xiangyu Wang; Yongsheng Xiang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

6.  Oxaliplatin promotes siMAD2L2‑induced apoptosis in colon cancer cells.

Authors:  Lu Ma; Xin Li; Xiaopeng Zhao; Haotong Sun; Feifei Kong; Yuanjie Li; Yu Sui; Fang Xu
Journal:  Mol Med Rep       Date:  2021-07-19       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.